THU0212 The improvement of ultrasonographic findings for 24 weeks may predict remission at 52 weeks...
THU0212 The improvement of ultrasonographic findings for 24 weeks may predict remission at 52 weeks in japanese rheumatoid arthritis patients treated with iguratimod therapy
About this item
Full title
Author / Creator
Kanayama, Y , Nagasaka, H , Shimotake, M , Miyachi, F , Fujita, K and Nagata, A
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
BackgroundIguratimod (IGU) suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6, IL-8, and monocyte chemoattractant protein 1 via inhibition of nuclear factor kappa B activation in cultured human synovial cells and human acute monocytic leukemia cells. We reported the clinical efficacy of IGU at ACR2014 and EULAR2015. How...
Alternative Titles
Full title
THU0212 The improvement of ultrasonographic findings for 24 weeks may predict remission at 52 weeks in japanese rheumatoid arthritis patients treated with iguratimod therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2033900960
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2033900960
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2017-eular.6948
